Scarica l'app Stockscreener
1.70
5.03%
-0.09
Dopo l'orario di chiusura:
1.65
-0.05
-2.94%
Adagene Inc Adr Borsa (ADAG) Ultime notizie
Why Adagene Inc. Depositary Receipt stock is a must watch in 2025Weekly Volume Report & Free Community Consensus Stock Picks - newser.com
Understanding Adagene Inc. Depositary Receipt’s price movement2025 Market Outlook & Community Supported Trade Ideas - newser.com
What’s the recovery path for long term holders of Adagene Inc. Depositary ReceiptMarket Rally & Entry Point Confirmation Alerts - newser.com
Adagene doses first patient in Phase 2 trial of muzastotug for MSS CRC - Investing.com
Adagene Inc. Initiates Phase 2 Clinical Trial of Muzastotug in Combination with KEYTRUDA for Colorectal Cancer - Quiver Quantitative
Adagene (NASDAQ: ADAG) opens randomized Phase 2 muzastotug + Keytruda trial in MSS CRC - Stock Titan
Adagene (NASDAQ:ADAG) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Grows By 66.4% - MarketBeat
CEO Change: Why analysts raise outlook for Adagene Inc. (Common Stock) (978) stockForecast Cut & High Accuracy Swing Entry Alerts - Trung tâm Dự báo KTTV quốc gia
Will Adagene Inc. Depositary Receipt stock recover faster than marketDip Buying & Safe Entry Trade Signal Reports - nchmf.gov.vn
Chart based analysis of Adagene Inc. Depositary Receipt trendsBreakout Watch & Advanced Swing Trade Entry Plans - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Adagene (NASDAQ:ADAG) - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Up 320.2% in September - Defense World
Adagene Inc. (ADAG) stock price, news, quote and history - Yahoo! Finance UK
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Significant Increase in Short Interest - MarketBeat
All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy - Yahoo Finance
How sentiment analysis helps forecast Adagene Inc. Depositary ReceiptMarket Growth Review & AI Driven Price Forecasts - newser.com
Are Medical Stocks Lagging Adagene (ADAG) This Year? - sharewise.com
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Update - MarketBeat
Lucid Capital Markets initiates coverage on Adagene stock with Buy rating - Investing.com India
Adagene Inc. Amends Collaboration Agreement with Exelixis to Advance SAFEbody Technology for Cancer Therapy - Quiver Quantitative
Adagene Expands SAFEbody® Collaboration and License - GlobeNewswire
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate - MarketScreener
Breakthrough Cancer Drug Technology: Adagene's 'Invisible' ADC Platform Expands to Third Program - Stock Titan
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Down 38.1% in August - Defense World
Using economic indicators to assess Adagene Inc. Depositary Receipt potential2025 Historical Comparison & Verified Short-Term Plans - newser.com
Quantitative breakdown of Adagene Inc. Depositary Receipt recent moveProduct Launch & High Return Trade Opportunity Guides - Newser
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Using data tools to time your Adagene Inc. Depositary Receipt exit2025 Historical Comparison & Risk Controlled Stock Pick Alerts - Newser
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Drops By 70.6% - MarketBeat
Adagene’s ADG126 to be Highlighted in Two Presentations at - GlobeNewswire
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - The Manila Times
Adagene Inc. Showcases ADG126 at CSCO Meeting with Promising Results in Advanced MSS Colorectal Cancer - Quiver Quantitative
30% Response Rate: Adagene's Novel Cancer Drug Shows Promise in Hard-to-Treat Colorectal Cancer Trial - Stock Titan
Former YERVOY developer Axel Hoos joins Adagene as advisor - Investing.com
Adagene Inc. Appoints Dr. Axel Hoos as Executive Advisor to Enhance Immuno-Oncology Initiatives - Quiver Quantitative
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - The Manila Times
Former $2.5B Scorpion CEO & YERVOY Developer: Adagene's CTLA-4 Platform Could Transform Cancer Care - Stock Titan
Is Adagene Inc. Depositary Receipt’s growth already priced inJuly 2025 Big Picture & Real-Time Buy Zone Alerts - خودرو بانک
Can Adagene Inc. Depositary Receipt maintain sales growthJuly 2025 Drop Watch & Free Real-Time Market Sentiment Alerts - خودرو بانک
What data driven models say about Adagene Inc. Depositary Receipt’s futureWeekly Stock Recap & Weekly High Momentum Picks - Newser
Adagene to Participate in Two Investor Conferences in September - The Manila Times
Biotech Innovator Adagene Scheduled for Major Wall Street Healthcare Conferences in September 2025 - Stock Titan
Will Adagene Inc. Depositary Receipt see short term momentumTrade Performance Summary & Smart Swing Trading Techniques - Newser
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? - Yahoo Finance
What moving averages say about Adagene Inc. Depositary ReceiptWeekly Profit Analysis & Daily Chart Pattern Signal Reports - Newser
HC Wainwright Issues Pessimistic Forecast for Adagene (NASDAQ:ADAG) Stock Price - Defense World
How to read the order book for Adagene Inc. Depositary Receipt2025 Volatility Report & Weekly High Conviction Trade Ideas - Newser
Q3 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World
H.C. Wainwright lowers Adagene stock price target to $7 on development path clarity - Investing.com
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):